期刊文献+

HPLC测定吉非替尼中的有关物质 被引量:3

Determination of the related substances in Gefitinib by HPLC
原文传递
导出
摘要 目的采用HPLC法测定吉非替尼中的有关物质。方法色谱柱为Phenomenex C_(18)柱(250 mm×4.6 mm,5μm),柱温40℃,流速1.0 m L·min^(-1),流动相为乙腈-乙酸铵缓冲液(1.5 g乙酸铵中加入1 L水溶解,加氨水调p H8.50±0.05),梯度洗脱,检测波长247 nm,进样量20μL。结果杂质Ⅰ~Ⅸ的线性范围分别为0.2101~1.2020、0.1940~3.880、0.2000~4.000、0.1920~3.8400、0.1952~3.904、0.2020~4.0400、0.1950~3.900、0.2022~4.0480、0.1920~3.8440μg·m L^(-1);检测限(S/N=3)分别为225、44.5、48.0、59.4、77.6、75.2、72.0、144、291 ng·m L^(-1)。结论所用方法灵敏、专属、准确,适用于吉非替尼有关物质的测定。 OBJECTIVE To establish an HPLC method for the determination of the related substances in Gefitinib. METHODS Analysis was carried out on a Phenomenex C18 column(250 mmx 4.6 mm ,5 μm) using acetonitrile- ammonium acetate buffer( 1.5 g of ammonium acetate with 1 L water, adding ammonia to adjust the pH to 8.50±0.05) as the mobile phase. The injection volume was 20 μL and the column temperature was 40 ℃. The detection wavelength was 247 nm, and the flow rate was 1.0 mL·min^-1. RESULTS The linear ranges of impurity Ⅰ- Ⅸ were 0. 2101 - 1. 2020 μg·m L^-1,0. 1940 - 3. 880 μg·m L^-1 ,0. 2000 - 4. 000 μg·m L^-1, 0. 1920 - 3. 840 μg·m L^-1 ,0. 1952 - 3. 9040 μg·m L^-1 ,0. 2020 - 4. 0400 μg·m L^-1 ,0. 1950 - 3. 900 μg·m L^-1 ,0. 2022 - 4. 0480 μg·m L^-1 and 0. 1920 - 3. 8440 μg·m L^-1, respectively. The limits of detection ( S/N = 3 ) was 225,44.5,48.0,59.4,77.6,75.2,72. 0,144 and 291 ng·m L^-1,respectively. CONCLUSION The method is sensitive, exclusive, accurate and suitable for the determination of the related substances in Gefitinib.
出处 《华西药学杂志》 CAS CSCD 2016年第5期526-528,共3页 West China Journal of Pharmaceutical Sciences
基金 广东省战略性新兴产业核心技术攻关计划资助项目(2012A080800012)
关键词 吉非替尼 高效液相色谱法 有关物质 梯度洗脱 检测限 稳定性 质量控制 Gefitinib HPLC Related substance Gradient elution Limits of detection Stability Quality control
  • 相关文献

参考文献6

  • 1Astra Zeneca plc (GB). Oncolytic EGF receptor tyrosine kina- seinhibitor Iressa^TM [ J ]. Drugs Future, 2002,27 (4) : 339 - 345.
  • 2Yang L, Parkin DM, Li LD, et at. Estimation and projection of the national profile of cancer mortality in China: 1991 - 2005 [ J]. British J Cancer,2004,90 ( 11 ) :2157 - 2166.
  • 3Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [ J]. CA Cancer J Chn ,2005 ,55 (2) :74 - 108.
  • 4Gandara D, Narayan S, Lara PN, et al. Integration of novel thera- peutics into combined modality therapy of locally advanced non - small cell lung cancer [ J ]. Clin Cancer Res, 2005,11 ( 13 ) : 5057 - 5062.
  • 5倪云峰,闫小龙,李小飞.吉非替尼对分子靶向抗癌药物研究的贡献是什么?[J].医学争鸣,2010,1(6):36-40. 被引量:2
  • 6陈帅,袁崇均,罗森,吴燕.HPLC测定易瑞沙中的吉非替尼及有关物质[J].华西药学杂志,2013,28(2):205-206. 被引量:7

二级参考文献13

  • 1Navada S,Lai P,Schwartz AG,et al.Temporal trends in small cell lung cancer:analysis of the national Surveillance Epidemiology and End Results(SEER)database[].Journal of Clinical Oncology.2006
  • 2Cadranel J,Quoix E,Baudrin L,et al.IFCT-0401 Trial:a phaseⅡstudy of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype[].J Thorac Oncol.2009
  • 3WW Ma,AA Adjei.Novel agents on the horizon for cancer therapy[].CA A Cancer Journal for Clinicians.2009
  • 4Jemal A,,Siegel R,Ward E,et al.Cancer statistics,2009[].CA A Cancer Journal for Clinicians.2009
  • 5TS Mok,YL Wu,SW Kim.Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma[].The New England Journal of Medicine.2009
  • 6Crino L,Cappuzzo F,Zatloukal P,et al.Gefitinib versus vinorelbine in chemotherapy - naive elderly patients with advanced non - small - cell lung cancer(INVITE):A randomized, phaseⅡstudy[].Journal of Clinical Oncology.2008
  • 7Inoue A,Suzuki T,Fukuhara T,et al.Prospective Phase II Study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations[].Journal of Clinical Oncology.2006
  • 8ES Kim,V Hirsh,T Mok,MA Socinski,R Gervais,Y Wu,L Li,CL Watkins,MV Sellers,ES Lowe,Y Sun,M Liao,K Osterlind,M Reck,A Armour,FA Shepherd,SM Lippman,J Douillard.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial[].The Lancet.2008
  • 9Rosell R,Moran T,Queralt C,et al.Screening for epidermal growth factor receptor mutations in lung cancer[].The New England Journal of Medicine.2009
  • 10A Jemal,R Siegel,E Ward,Y Hao,J Xu,T Murray.Cancer statistics,2008[].CA A Cancer Journal for Clinicians.2008

共引文献7

同被引文献15

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部